Wexford Capital’s Ionis Pharmaceuticals IONS Stock Holding History

Wexford Capital’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,192	Closed	-$78K	–	448
2025 Q3	$78K	Sell	1,192 -3,557	-75%	-$174K	0.01%	255
2025 Q2	$188K	Buy	+4,749	New	+$155K	0.05%	171
2019 Q4	–	Sell	-15,385	Closed	-$922K	–	140
2019 Q3	$922K	Buy	15,385 +5,000	+48%	+$326K	0.13%	82
2019 Q2	$667K	Sell	10,385 -4,000	-28%	-$283K	0.08%	98
2019 Q1	$1.17M	Sell	14,385 -18,195	-56%	-$1.17M	0.1%	65
2018 Q4	$1.76M	Hold	32,580	–	–	0.15%	42
2018 Q3	$1.68M	Hold	32,580	–	–	0.11%	87
2018 Q2	$1.36M	Buy	32,580 +25,000	+330%	+$1.11M	0.09%	79
2018 Q1	$334K	Buy	+7,580	New	+$385K	0.02%	98
2014 Q2	–	Sell	-14,700	Closed	-$635K	–	138
2014 Q1	$635K	Buy	+14,700	New	+$713K	0.05%	138

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Wexford Capital's IONS Position: Q4 2025 in Review

Wexford Capital sold out of Ionis Pharmaceuticals (IONS) in Q4 2025, closing a stake of 1,192 shares — an estimated $78K sold.

Wexford Capital first reported a position in IONS in Q1 2014 and held it in 10 quarters. The position peaked at $1.76M in Q4 2018. 491 funds tracked by Wall St. Rank hold IONS as of Q4 2025.

Wexford Capital reported no remaining Ionis Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Wexford Capital sold 1,192 Ionis Pharmaceuticals shares in Q4 2025, an estimated $78K.
Wexford Capital first reported a position in Ionis Pharmaceuticals in Q1 2014 and held it in 10 quarters.
Wexford Capital's Ionis Pharmaceuticals position peaked at $1.76M in Q4 2018.
491 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2025.

Based on Wexford Capital's 13F filing for Q4 2025, filed 13 Feb 2026.